Yanagi Teruki

写真a

Title

Associate Professor
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Associate Professor  

To the head of this page.▲

Academic degree 【 display / non-display 】

  • Hokkaido University -  PhD

To the head of this page.▲

Affiliated academic organizations 【 display / non-display 】

  • 　
    　
    　
     

    THE JAPANESE SOCIETY FOR INVESTIGATIVE DERMATOLOGY 

  • 　
    　
    　
     

    THE JAPANESE DERMATOLOGICAL ASSOCIATION 

  • 　
    　
    　
     

    THE JAPANESE CANCER ASSOCIATION 

To the head of this page.▲

Research Interests 【 display / non-display 】

  • 皮膚腫瘍学

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life Science / Dermatology

To the head of this page.▲

Published Papers 【 display / non-display 】

  • The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study

    Fujisawa, Y; Fujimura, T; Matsushita, S; Yamamoto, Y; Uchi, H; Otsuka, A; Funakoshi, T; Miyagi, T; Hata, H; Gosho, M; Kambayashi, Y; Aoki, M; Yanagi, T; Ohira, A; Nakamura, Y; Maeda, T; Yoshino, K

    BRITISH JOURNAL OF DERMATOLOGY ( British Journal of Dermatology )  183 ( 5 ) 831 - 839   2020.11 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    Background: Taxanes are the current first-line treatment for advanced cutaneous angiosarcoma (CAS) for patients who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. However, no effective second-line therapy for such patients has been established. Methods: We designed a single-arm prospective observational study of eribulin mesylate (ERB) administered at a dose of 1·4 mg m−2 on days 1 and 8 in a 21-day cycle. Patients with advanced CAS who were previously treated with a taxane and were scheduled to begin ERB treatment were enrolled. The primary endpoint was overall survival (OS) and the secondary endpoints were response rate (RR), progression-free survival (PFS) and toxicity assessment. Results: We enrolled a total of 25 patients. The median OS and PFS were 8·6 months and 3·0 months, respectively. The best overall RR was 20% (five of 25). In total, 16 grade 3/4 severe adverse events (SAEs) occurred; however, all patients recovered. Patients who achieved partial response or stable disease as best response had longer OS than those with progressive disease (median OS not reached and 3·3 months, respectively; P < 0·001). Patients who did not experience SAEs showed longer OS than those who did (median OS 18·8 months and 7·5 months, respectively; P < 0·05). Patients with distant metastasis had shorter median OS than those with locoregional disease, but without statistically significant difference. Conclusions: ERB showed a promising RR and is a potential candidate for second-line treatment for patients with CAS, after treatment with taxanes. However, owing to the occurrence of SAEs in over half of the participants, caution should be exercised regarding ERB use in elderly patients. What is already known about this topic?. Taxanes are the current first-line treatment for patients with advanced cutaneous angiosarcoma (CAS) who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. No effective therapy for taxane-resistant CAS has been established thus far. Eribulin suppresses microtubule polymerization and elicits an antitumour effect similar to that of taxanes. What does this study add?. In our single-arm prospective observational study to evaluate the efficacy of eribulin for treating patients with advanced CAS who previously received taxanes, the median overall survival and progression-free survival were 8·6 and 3·0 months, respectively. Response rates at weeks 7, 13 and 25 were 20%, 17% and 14%, respectively. Although 16 grade 3/4 severe adverse events occurred, all patients recovered. Eribulin showed a promising response rate and is a potential candidate for second-line treatment in CAS after taxane treatment. Linked Comment: Smrke and Benson. Br J Dermatol 2020; 183:797–798.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Ultrasonographic features of myxoid neurofibroma: Report of a case on the abdomen

    Akihiro Orita, Shinya Kitamura, Takuya Maeda, Ai Shimizu, Teruki Yanagi

    The Journal of Dermatology   48 ( 1 ) e9-e10   2020.10 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019

    F.M. Ghazawi, N. Iga, R. Tanaka, Y. Fujisawa, K. Yoshino, C. Yamashita, Y. Yamamoto, T. Fujimura, T. Yanagi, H. Hata, S. Matsushita, M. Le, S.F. Roy, F. Lagacé, Y. Ishida, K. Kabashima, A. Otsuka

    Journal of the European Academy of Dermatology and Venereology ( Wiley )    2020.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI

  • Loss of dynamin-related protein 1 (Drp1) does not affect epidermal development or UVB-induced apoptosis but does accelerate UVB-induced carcinogenesis

    Teruki Yanagi, Shinya Kitamura, Keisuke Imafuku, Asuka Suto, Takuya Maeda, Shinya Tanaka, Hiromi Sesaki, Riichiro Abe, Hiroshi Shimizu

    Journal of Dermatological Science ( Elsevier {BV} )  99 ( 2 ) 109 - 118   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    BACKGROUND: Mitochondrial morphology is controlled by fission and fusion. Dynamin-related protein 1 (Drp1, dynamin-1-like protein (Dnml1)) regulates mitochondrial fission, which is associated with cell division and apoptosis. We previously reported that DRP1 is indispensable for cell growth in cutaneous squamous cell carcinoma. However, little is known about Drp1 in normal epidermis/keratinocytes. OBJECTIVES: We investigated the function of Drp1 in normal epidermis/keratinocytes. METHODS: Epidermis-specific Drp1 knockout (EKO) mice were analyzed. RESULTS: Epidermal development in the EKO mice were indistinguishable from those in the wild-type (WT) mice. Ultrastructural analysis and immunohistochemistry revealed that the mitochondria of keratinocytes in the EKO mice were neither elongated nor constricted. Drp1 knockdown did not diminish the cell growth of normal human keratinocytes. Both in vivo and in vitro, UVB-induced apoptosis in the EKO epidermis and keratinocytes did not differ from that in the WT mice. In chronic UVB-irradiation, the loss of Drp1 sensitized the epidermis to the development of skin tumors. Clinically, DRP1 is expressed more highly in sun-exposed skin than in non-exposed skin in individuals under age 40, but not in those over age 60. CONCLUSION: EKO mice demonstrate that Drp1 is dispensable for the development and apoptosis of the epidermis. Drp1 plays critical roles in malignant tumors; thus, the molecular machinery of mitochondrial dynamics involving Drp1 could be a novel therapeutic target for malignant keratinocytic lesions. On the other hand, the anti-tumorigenic role of Drp1 in chronic UVB-induced carcinogenesis need to be further investigated.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Drp1 expression levels correlate with clinical stage in extramammary Paget's disease.

    Kitamura S, Yanagi T, Maeda T, Shimizu H

    Journal of the European Academy of Dermatology and Venereology : JEADV   34 ( 9 ) e510 - e513   2020.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

display all >>

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

  • Genome-wide screening of the key molecules for metastasizing collagen VII-deficient squamous cell carcinoma.

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2019.04  -  2022.03 

    Direct: 3,300,000 (YEN)  Overheads: 4,290,000 (YEN)  Total: 990,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2018.04  -  2021.03 

    Direct: 3,500,000 (YEN)  Overheads: 4,550,000 (YEN)  Total: 1,050,000 (YEN)

  • Gene profiling for pressure ulcer

    Grant-in-Aid for Scientific Research(B)

    Project Year: 2017.07  -  2020.03 

    Direct: 14,300,000 (YEN)  Overheads: 18,590,000 (YEN)  Total: 4,290,000 (YEN)

  • The critical role for fibroblast in RDEB-SCC patients

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2017.04  -  2020.03 

    Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

To the head of this page.▲